Stocks Health care RMD
NYSE · Health careResmed Inc (RMD)
Resmed Inc reported revenue of $5.7B in fiscal 2026, up 9.9% from a year earlier. Net income was $1.5B, a net margin of 26.9%. Operating cash flow minus capital spending left $1.6B of free cash flow in fiscal 2026. At June 30, 2026 it held $1.5B in cash against $399.4M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on August 13, 2026.
Key facts about Resmed Inc
- Net worth
- Resmed Inc has a market value (market cap) of $33.8B at the latest share price, and shareholders' equity of $6.6B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $5.7B (+9.9% year on year), with net income of $1.5B.
- Cash flow
- In fiscal 2026 operations brought in $1.8B of cash; after $156.3M of capital spending, free cash flow was $1.6B.
- Latest report
- The latest periodic report (annual report, 10-K) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Resmed Inc's next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Resmed Inc declared dividends of $2.40 per share in fiscal 2026, a yield of 1.03% at the current price.
What Resmed Inc does
Resmed Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker RMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $5.7B | $1.5B | $10.43 | $1.6B |
| 2025 | $5.1B | $1.4B | $9.51 | $1.7B |
| 2024 | $4.7B | $1B | $6.92 | $1.3B |
| 2023 | $4.2B | $897.6M | $6.09 | $573.6M |
| 2022 | $3.6B | $779.4M | $5.30 | $216.3M |
| 2021 | $3.2B | $474.5M | $3.24 | $634M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RMD ranks in Health care
Dividends
Resmed Inc declared $2.40 per share in fiscal 2026. At the current price that is a yield of 1.03%. It paid out $349.7M in cash dividends, 23% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2026 | $2.40 | $349.7M | 23% |
| 2025 | $2.12 | $310.9M | 22% |
| 2024 | $1.92 | $282.3M | 28% |
| 2023 | $1.76 | $258.3M | 29% |
| 2022 | $1.68 | $245.3M | 31% |
| 2021 | $1.56 | $226.7M | 48% |
Latest SEC filings
What Resmed Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026
- October 1, 2026Additional proxy material DEFA14A
- October 1, 2026Proxy statement DEF 14A
- September 1, 2026Other event 8-K
- August 17, 2026
- August 13, 2026Annual report 10-K · period to June 30, 2026Revenue rose 9.9% to $5.7B versus the prior year; diluted EPS $10.43 versus $9.51.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- July 7, 2026
- May 26, 2026
What is RMD worth? A DCF from its reported cash flow
Insider trades
What the people running Resmed Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Farrell Peter CDirector | Soldpre-planned (10b5-1) | 970 | $227.7K |
| August 14, 2026 | Bloomer AaronChief Financial Officer | Received as pay | 9,072 | - |
| August 14, 2026 | Farrell Michael J.Chairman and CEO, Director | Received as pay | 13,547 | - |
| August 14, 2026 | Rider Michael JGlobal General Counsel | Received as pay | 3,230 | - |
| August 14, 2026 | Leong JustinChief Product Officer | Received as pay | 6,461 | - |
| August 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Exercised options | 4,991 | $730.4K |
| August 7, 2026 | Farrell Michael J.Chairman and CEO, Director | Soldpre-planned (10b5-1) | 4,991 | $1M |
| August 5, 2026 | Farrell Peter CDirector | Soldpre-planned (10b5-1) | 8,000 | $1.8M |
Who owns RMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 8.21% | April 29, 2026 |
| AustralianSuper Pty Ltd13G, passive | 5.7% | August 7, 2026 |
| Vanguard Portfolio Management13G, passive | 5.41% | April 29, 2026 |
Largest institutional holders
Insiders
15 insiders reported holding 768,458 shares in total, about $180.8M at the last price.
| Holder | Shares |
|---|---|
| Farrell Michael J.Chairman and CEO, Director | 479,803 |
| Sandercock BrettChief Financial Officer | 83,495 |
| Leong JustinChief Product Officer | 64,517 |
| Farrell Peter CDirector | 51,803 |
| Taylor Ronald RDirector | 24,771 |
| Rider Michael JGlobal General Counsel | 12,718 |
| Gill HarjitDirector | 10,940 |
| Drexler KarenDirector | 10,602 |
| Bloomer AaronChief Financial Officer | 9,072 |
| Tan DesneyDirector | 6,002 |
Questions about RMD
What does Resmed Inc do?
Resmed Inc is a company in the Health care sector, listed on NYSE as RMD. Its shares trade on NYSE under the ticker RMD.
What is Resmed Inc's net worth?
Resmed Inc has a market value (market cap) of $33.8B at the latest share price, and shareholders' equity of $6.6B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Resmed Inc profitable?
Yes. In fiscal 2026 it reported net income of $1.5B on revenue of $5.7B, a net margin of 26.9%.
How much revenue does Resmed Inc make?
In fiscal 2026 Resmed Inc reported revenue of $5.7B. That is 9.9% more than a year earlier.
When did Resmed Inc last report?
Its most recent periodic report is the annual report (10-K) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the annual report to shareholders from October 1, 2026.
When is Resmed Inc's next earnings report?
Resmed Inc's next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Resmed Inc pay a dividend?
Yes. Resmed Inc declared dividends of $2.40 per share in fiscal 2026, a yield of 1.03% at the current price.
Similar companies
Compare RMD with
Follow RMD
Get an email when Resmed Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Resmed Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.